About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Systane Complete Multi-symptom Relief | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNANCT05056155

Systane Complete Multi-symptom Relief

The purpose of this study is to demonstrate effective symptom relief with the use of Systane Complete among subjects with dry eye disease (DED).

Lead sponsor: Alcon Research•4 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Alcon Research

Subjects will be expected to attend a screening/baseline visit and one additional visit at Day 28 (± 2 days), with a telephone call visit conducted at Day 14 (± 2 days). Individual duration of subject participation will be approximately 28 days.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Able to understand and sign an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent form.
•Willing and able to attend all study visits as required per protocol.
•Have dry eye symptoms as specified in the protocol.
•Willing to discontinue use of all habitual artificial tear supplements for the entire study duration.

Exclusion Criteria

•Ocular conditions as specified in the protocol.
•Contact lens use within one week prior to screening visit.
•Use of medications as specified in the protocol.
•Pregnant or breast feeding.

Related studies

RECRUITINGPhase 2

Dose-Finding Study of HUC1-394 in Participants With Dry Eye Disease

NCT07656688 · Dry Eye Disease (DED)

Impact of GLP-1 Receptor Agonists on Dry Eye Disease in Patients With Type 2 Diabetes Mellitus and Obesity

NCT07605572 · Dry Eye Disease (DED), Diabete Mellitus, and more

RECRUITINGPhase 4

A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study

NCT07463950 · Dry Eye Disease (DED)

Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hyaluronic Acid 0.3% (FBV_01) vs Hyaluronic Acid 0.3% in Subjects in the Treatment From Moderate to Severe DED

NCT07412860 · Dry Eye Syndromes, Dry Eye Disease (DED)

A Study on the Correlation Between Tear Iron Levels and the Severity of Dry Eye Disease.

NCT07363824 · Dry Eye Disease, Iron

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 29, 2022Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment119

Start dateNov 2021

Last updatedMar 29, 2022

Condition

Dry Eye Disease

Locations shown

Alcon Investigator 1455

Kansas City, Missouri

Alcon Investigator 8046

Granville, Ohio

Alcon Investigator 6313

Powell, Ohio

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 29, 2022Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions